Literature DB >> 10447513

PPARgamma, the ultimate thrifty gene.

J Auwerx1.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) quickly evolved over the last decade from a new orphan receptor to one of the best characterized nuclear receptors. This fast pace in PPARgamma research was triggered by two main discoveries. Firstly, that PPARgamma was shown to have a key role in adipogenesis and be a master controller of the "thrifty gene response" leading to efficient energy storage. Secondly, the discovery that its synthetic ligands, the thiazolidinediones, are promising insulin sensitizing drugs, which are currently being developed for the treatment of Type II (non-insulin-dependent) diabetes mellitus. More recently this nuclear receptor emerged from a role limited to metabolism (diabetes and obesity) to a power player in general transcriptional control of numerous cellular processes, with implications in cell cycle control, carcinogenesis, inflammation, atherosclerosis and immunomodulation. This widened role of PPARgamma will certainly initiate a new flurry of research, which will not only refine our current often partial knowledge of PPARgamma but more importantly also establish that this receptor has a definite role as a primary link adapting cellular, tissue and whole body homeostasis to energy stores.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447513     DOI: 10.1007/s001250051268

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  121 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Insights into insulin resistance and type 2 diabetes from knockout mouse models.

Authors:  T Kadowaki
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.

Authors:  Y Park; B D Freedman; E J Lee; S Park; J L Jameson
Journal:  Diabetologia       Date:  2003-03-07       Impact factor: 10.122

4.  Peroxisome proliferator-activated receptor gamma gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries.

Authors:  W Koch; V Jung; N von Beckerath; A Schömig; A Kastrati
Journal:  Diabetologia       Date:  2004-05-20       Impact factor: 10.122

Review 5.  Fatty acid binding proteins--the evolutionary crossroads of inflammatory and metabolic responses.

Authors:  Liza Makowski; Gökhan S Hotamisligil
Journal:  J Nutr       Date:  2004-09       Impact factor: 4.798

Review 6.  Candidate genes for type 2 diabetes.

Authors:  Hemang Parikh; Leif Groop
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

Review 7.  [Genetics of type 2 diabetes].

Authors:  Y Böttcher; P Kovacs; A Tönjes; M Stumvoll
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

Review 8.  New pharmacologic agents for diabetes.

Authors:  C J Bailey
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

9.  The association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene with the metabolic characteristics in Chinese women with polycystic ovary syndrome.

Authors:  Jiejin Yang; Hao Gong; Wei Liu; Tao Tao
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

Review 10.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.